skip to main content, skip to Quick links, or skip to Search

main content

clinical studies

Nerve Growth Factor Study

orange cat with purple iris flowers in background

Evaluation of the Pain Alleviating Effects of NV-02 in Cats Suffering from Degenerative Joint Disease-Associated Pain


We are seeking participants for a trial of a new biological compound, an antibody, that is being used to treat pain. It is a feline version of a compound being tested for arthritis pain control in humans. The treatment is NOT a non-steroidal anti-inflammatory (NSAID), and will administered once subcutaneously with an expected duration of effect of several weeks.

Description: The purpose of this study is to evaluate the efficacy of NV-02, an antibody to nerve growth factor, for the treatment of osteoarthritis pain in cats. This is a blinded, placebo controlled, pilot study. Thirty-six cats will be recruited into this study. Each cat will be evaluated over an 11-week period for changes in pain and mobility using various owner assessments, activity monitors, kinetic variables and veterinarian-assessed joint pain.

Eligibility:

Cats must satisfy the following criteria:

Cats with the following conditions will be excluded:

Owner obligations:

We need owners of cats to be able to commit to the following:

Study incentives: The study will cover the cost of the examination, hospitalization, blood work and urinalysis, radiographs, and study drug. No other financial incentives are offered for participation. 

 

Contact:
Comparative Pain Research Laboratory at North Carolina State University, College of Veterinary Medicine (919) 513-6854 or email andrea_thomson@ncsu.edu

.